AstraZeneca pauses coronavirus vaccine trial, shares slip on rollout doubts By Reuters

AstraZeneca pauses coronavirus vaccine trial, shares slip on rollout doubts


2/2
© Reuters. FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York

2/2

By Ludwig Burger

LONDON (Reuters) – AstraZeneca’s (L:) suspension of global trials of its experimental coronavirus vaccine after an unexplained illness in a study subject in Britain has cast doubt on prospects for an early rollout.

The vaccine, which Britain’s AstraZeneca is developing with the University of Oxford, has been described by the World Health Organization as probably the world’s leading candidate and the furthest developed.

AstraZeneca said on Tuesday it had paused trials, including late-stage ones, to allow an independent committee to review safety data, and it was working to minimise any potential impact on the timeline.

“It is obviously a challenge to this particular vaccine trial,” Britain’s Health Secretary Matt Hancock told Sky News.

The patient was suffering from neurological symptoms associated with a rare spinal inflammatory disorder called transverse myelitis, said Chief Executive Pascal Soriot, according to Stat News, citing investors who had listened to a call it said was organised by J.P. Morgan.

The diagnosis has yet to be confirmed, but the patient is recovering and will likely be discharged from the hospital soon, the CEO reportedly added.

The pause follows reports that the United States was aiming for fast-track authorization or approval before November’s presidential election.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *


About us

InvestLab is a financial services technology company focused on the global trading market. Founded in 2010 in Hong Kong, the company develops trading, market data, and social research products that enable individual investors and small to mid-size brokers to access global markets. We provide brokers and financial institutions cross border capabilities for retail investors into 43 markets globally.


CONTACT US

CALL US ANYTIME